30 years of drug discovery / development experience in pharmaceutical industry and academia
Sandoz: 1979 - 1981; 1983 - 1997; Novartis: 1997 - Nov 2012; Scripps: 2004 - present
The University of Melbourne: December 2012 - present
Management of pharmacology research groups, drug discovery programmes, compound profiling teams, translational biology.
Responsibility for extensive cross disciplinary internal and external interactions / collaborations.
Leadership of large learned societies and numerous editorial and academic activities.
Establishment of Project Mercury (BioCurate PTY Ltd) between Monash University and University of Melbourne: an $ 80 Mio translational Biomed enterprise with $ 10 Mio support from Vic Govt.
Therapeutic / other areas of interest:
Sleep disorders, epilepsy, migraine, schizophrenia, anxiety / depression, bipolar disorders, panic, PTSD, Parkinson’s disease / other neurological disorders (MS/ALS/HD/fragile X), irritable bowel syndrome, acromegaly, gastroenteropancreatic and other tumors, hypertension, pulmonary hypertension. PET and other imaging approaches / radiotherapy / electrophysiology / sleep EEG, gene expression profiling, proteomics, SiRNA, epigenetics of mental retardation & Autism Spectrum Disorders.
Molecular targets characterised:
Monoamine receptors and transporters: 5-HT receptors (all except 5-HT5 and 5-HT6), adrenoceptors (alpha1,2 and beta1,2), dopamine (D2, D3 and D4), 5-HTT, NET, DAT. Peptide and other receptors: Orexin, somatostatin (sst1-sst5), endothelin, CRF, NPS, NPY1,2, neurokinin NK1, sphingolipid S1P1-5, Glutamate (mGluR5, 7), GABAB. Ligand-gated channels and other receptors: 5-HT3, Glutamate (AMPA, Kainate, NMDA), Nicotinic (alpha4beta2, alpha7), GABAA and peripheral benzodiazepine receptors, FMR1 and FMRP.